Last updated on February 2018

A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed Multi Eye Drops in the Management of Dry Eye

Brief description of study

The primary objectives of this investigation are to show that the performance of CBL-101 Eye Drops is non-inferior to that of Vismed Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days, and to assess the safety of CBL-101 Eye Drops during a 90-day period with treatment administered 3 to 6 times per day.

Detailed Study Description

Study duration will be approximately 15 weeks from screening to the last visit. Subjects will visit the clinic approximately 5 times.

Clinical Study Identifier: NCT02975102

Contact Investigators or Research Sites near you

Start Over

Pr Mortemousque

Pr Mortemousque private office
Bordeaux, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.